|
Comparison of Basal Versus Stimulated Serum Thyroglobulin Levels to Assess Treatment Response in Papillary Thyroid Carcinoma
|
A Gholami    , H Gholinia , SH Mousavie Anijdan * |
| 3.Department of Radiation Technology, Faculty of Allied Medical Sciences, Babol University of Medical Sciences, Babol, I.R.Iran. , shmosavia@gmail.com |
|
|
Abstract: (203 Views) |
Background and Objective: Papillary Thyroid Carcinoma (PTC) is the most common differentiated thyroid carcinoma. Persistent or recurrent disease occurs in approximately 20% of patients after treatment. Measurement of serum thyroglobulin (Tg) levels is one of the most important methods used for residual or recurrent disease management. The present study was conducted to investigate the role and significance of comparing two methods of measuring basal thyroglobulin (BTg) and stimulated thyroglobulin (STg) to assess treatment response and patient follow-up.
Methods: In this cross-sectional study, patients with papillary thyroid carcinoma undergoing treatment were classified into three categories: excellent response (ER), indeterminate response (IR), and biochemical incomplete response (BIR) based on imaging tests and Tg levels. The primary outcome measure was the change in treatment response one year after initial treatment, which was achieved by comparing STg with BTg assessments.
Findings: A total of 126 patients, including 96 women and 30 men, were assessed. One year after initial treatment, 28 patients (22.2%) showed a change in their classification when the treatment response based on BTg was compared with STg. Sixteen patients (12.7%) had a worse response, and their classification changed from the ER group to other groups. After measuring STg, structural recurrence was identified in 5 patients during the follow-up period. Based on STg, the highest recurrence was in the BIR group, followed by the IR group, which was statistically significant compared to the ER group (p=0.001).
Conclusion: The results of this study demonstrated that compared to BTg, STg measurement better defines treatment response in low- or intermediate-risk patients when classified as indeterminate (IR and BIR). However, when BTg provides excellent response, STg measurement is not required. |
|
| Keywords: Differentiated Thyroid Carcinoma, Radioactive Iodine Therapy, Basal Thyroglobulin, Stimulated Thyroglobulin, Total Thyroidectomy. |
|
|
Full-Text [PDF 284 kb]
(29 Downloads)
|
Type of Study: Research |
Subject:
Nuclear Medicine
Received: 2024/11/10 | Accepted: 2025/01/20 | Published: 2025/12/14
|
|
|
|
|
|
|
| Send email to the article author |
|
|
